148 related articles for article (PubMed ID: 33738509)
1. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.
Ozturk K; Soylu E; Cayci Z
Neuroradiology; 2021 Nov; 63(11):1801-1810. PubMed ID: 33738509
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
[TBL] [Abstract][Full Text] [Related]
5. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
Lu J; Li X; Li H
Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
[TBL] [Abstract][Full Text] [Related]
6. Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.
Ryoo I; Choi SH; Kim JH; Sohn CH; Kim SC; Shin HS; Yeom JA; Jung SC; Lee AL; Yun TJ; Park CK; Park SH
PLoS One; 2013; 8(8):e71704. PubMed ID: 23977117
[TBL] [Abstract][Full Text] [Related]
7. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
Crisi G; Filice S
J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract][Full Text] [Related]
9. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
[TBL] [Abstract][Full Text] [Related]
10. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
[TBL] [Abstract][Full Text] [Related]
11. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
12. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
13. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.
Siakallis L; Topriceanu CC; Panovska-Griffiths J; Bisdas S
Neuroradiology; 2023 Jul; 65(7):1111-1126. PubMed ID: 37173578
[TBL] [Abstract][Full Text] [Related]
14. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
15. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
16. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
17. Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.
Ozturk K; Soylu E; Cayci Z
Eur J Radiol; 2021 Aug; 141():109784. PubMed ID: 34051685
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
[TBL] [Abstract][Full Text] [Related]
19. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
